This corrigendum refers to a study reporting that activation of α7 nicotinic acetylcholine receptors reduced α‑synuclein pathology in both brain and gut in a subacute MPTP mouse model of Parkinson’s disease.

If robust, the finding supports a druggable α7 nAChR pathway that modulates α‑synuclein and the gut–brain axis—offering translational and repurposing potential—but interpretation is limited by the preclinical MPTP model, lack of the original abstract here, and the fact this document is a…